Cannara Biotech (DE:8CB0)
FRANKFURT:8CB0
8CB0 Stock Chart & Stats
€1.08
<€0.01(1.81%)
At close: 4:00 PM EST
€1.08
<€0.01(1.81%)
Day’s Range― - ―
52-Week Range€0.69 - €1.24
Previous CloseN/A
Volume1.00
Average Volume (3M)0.00
Market Cap
€101.25M
Enterprise Value€183.30M
Total Cash (Recent Filing)€16.52M
Total Debt (Recent Filing)€34.85M
Price to Earnings (P/E)13.1
Beta0.29
Next Earnings
Jul 14, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.13
Shares Outstanding98,782,150
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.64
Price to Sales (P/S)1.57
P/FCF Ratio12.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.92Price Target Upside77.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.08
Revenue Forecast (FY)€79.58M
Bulls Say, Bears Say
Bulls Say
Profitability / MarginsSustained high gross and operating margins indicate durable cost control and favorable product economics versus peers. Strong margins support reinvestment in cultivation and processing, provide a cushion through industry cycles, and underpin consistent return generation for shareholders over months.
Improving LeverageDeclining leverage improves financial flexibility and reduces interest exposure, giving management more room for capital allocation and operational investments. Lower leverage combined with rising equity reduces refinancing risk and strengthens resilience to demand or margin shocks.
Revenue Growth TrendConsistent revenue expansion over multiple periods reflects steady market penetration in Canada's regulated channels and effective wholesale distribution. Ongoing top-line growth helps spread fixed cultivation costs and supports durable margin maintenance and scale economics.
Bears Say
Free Cash Flow VolatilityMaterial variability in free cash flow, including the recent decline and prior negative FCF years, constrains the firm's ability to consistently self-fund capex, inventory build or strategic initiatives. Persistent volatility increases reliance on external financing and raises execution risk.
Material Absolute DebtAlthough leverage metrics improved, an absolute debt load near $35M remains significant for a mid‑sized cannabis operator. This debt can pressure cash flow if margins compress, limit strategic flexibility, and elevate refinancing or covenant risks during industry headwinds.
Earnings Normalization RiskA modest decline in trailing net income versus the prior year suggests potential normalization after a stronger period. This may signal sensitivity to pricing, cost inflation or mix shifts, which could pressure reinvestment capacity and long‑term return profiles if sustained.
Cannara Biotech News
8CB0 FAQ
What was Cannara Biotech’s price range in the past 12 months?
Cannara Biotech lowest stock price was €0.69 and its highest was €1.24 in the past 12 months.
What is Cannara Biotech’s market cap?
Cannara Biotech’s market cap is €101.25M.
When is Cannara Biotech’s upcoming earnings report date?
Cannara Biotech’s upcoming earnings report date is Jul 14, 2026 which is in 34 days.
How were Cannara Biotech’s earnings last quarter?
Cannara Biotech released its earnings results on Apr 14, 2026. The company reported €0.012 earnings per share for the quarter, missing the consensus estimate of €0.031 by -€0.019.
Is Cannara Biotech overvalued?
According to Wall Street analysts Cannara Biotech’s price is currently Undervalued.
Does Cannara Biotech pay dividends?
Cannara Biotech does not currently pay dividends.
What is Cannara Biotech’s EPS estimate?
Cannara Biotech’s EPS estimate is 0.03.
How many shares outstanding does Cannara Biotech have?
Cannara Biotech has 98,782,150 shares outstanding.
What happened to Cannara Biotech’s price movement after its last earnings report?
Cannara Biotech reported an EPS of €0.012 in its last earnings report, missing expectations of €0.031. Following the earnings report the stock price went down -9.677%.
Which hedge fund is a major shareholder of Cannara Biotech?
Currently, no hedge funds are holding shares in DE:8CB0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cannara Biotech
Cannara Biotech Inc., alongside its affiliated entities, specializes in the indoor cultivation, processing, and distribution of cannabis and related products across Canada. The company operates with a dual business model, encompassing both cannabis operations and real estate activities. Its diverse product portfolio is marketed under distinct brand names such as TRIBAL, nugz, and ORCHID CBD. Distribution is managed through both wholesale channels and online retail platforms. Established in 2017, Cannara Biotech Inc. maintains its headquarters in Saint-Laurent, Canada.
8CB0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance with record-breaking metrics and significant market share growth in key regions and product categories. However, there are challenges in maintaining market share in certain regions and managing cash flow effectively.View all DE:8CB0 earnings summaries8CB0 Stock 12 Month Forecast
Average Price Target
€1.92
▲(77.80% Upside)
Technical Analysis
Jushi Holdings
―
Organigram Global
―
Auxly Cannabis Group
―
Cannabist Company Holdings
―
Grown Rogue International
―
Options Prices
Currently, No data available
---